Bozitinib plus chemotherapy after surgery for MET-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining a targeted drug (bozitinib) with chemotherapy after lung cancer surgery to see if it can help prevent the cancer from coming back. The study is for people with a specific MET gene change in their lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have non-small cell lung cancer (adenocarcinoma) that shows a specific MET gene change
- Your cancer must be stage IIA to IIIC, meaning it hasn't spread to distant organs
- You must be able to have surgery to remove the cancer, and you must not have had chemotherapy or radiation before
- Your overall health and organ function must be good enough (like normal blood counts, liver, kidney, and lung function)
- You cannot have other treatable gene changes (like EGFR or ALK) or brain metastases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving targeted therapy before and after surgery helps people with a specific type of lung cancer (non-small cell lung cancer with a BRAF or MET mutation). The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
This trial tests a targeted drug called vebreltinib given before surgery to people with a specific type of non-small cell lung cancer that has a MET gene change. The goal is to see if it can shrink the tumor enough to make surgery more successful.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This trial tests whether taking vebreltinib before surgery can help shrink lung cancer tumors with a specific genetic change (MET alteration). It may make surgery more effective for people with stage III non-small cell lung cancer.
This trial tests a new targeted drug, vebreltinib, combined with standard chemotherapy as the first treatment for advanced non-small cell lung cancer that has a specific marker called MET overexpression. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
Hear when a new MET Exon 14 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.